Head-to-head · Cost-Efficiency Index
Henry Meds vs Vaylen
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Henry Meds
People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Visit Henry MedsVaylen
Cost-first shoppers who want gLP-1-focused care with oral and injectable options across all 50 states.
Visit VaylenThe verdict
Henry Meds takes it, leading the Cost-Efficiency Index 81 to 80. A transparent flat-fee pioneer — the pricing is clean and modelable, but it now sits at the higher end, so the value per dollar has slipped. Vaylen still earns a B− — Cost-first shoppers who want gLP-1-focused care with oral and injectable options across all 50 states.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Henry Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Henry Meds | Vaylen |
|---|---|---|
| Cost-Efficiency Index | 81/100 | 80/100 |
| Semaglutide / mo | $249/mo | $179/mo (compounded) |
| Tirzepatide / mo | $349/mo | $239/mo (compounded) |
| Semaglutide / yr (modeled) | $2,988 | $2,148 |
| Tirzepatide / yr (modeled) | $4,188 | $2,868 |
| Coverage | Multi-state | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #30 | #34 |
Henry Meds
81/100Where the value is
- Simple, transparent flat-fee model that's easy to model
- Well-established brand
- Both molecules disclosed
The tradeoffs
- Higher per-month cost than many newer entrants weakens value
- Compounded only
Vaylen
80/100Where the value is
- Pure GLP-1 specialist — not a multi-category telehealth platform
- All 50 states coverage with licensed clinicians
- Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
The tradeoffs
- Compounded semaglutide at $179/mo is mid-range (not the cheapest)
- Brand-name options at near-retail pricing ($997-$1,086/mo)
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.